Carrier Screening Market in terms of revenue was estimated to be worth $2.2 billion in 2023 and is poised to reach $5.4 billion by 2028, growing at a CAGR of 19.7% from 2023 to 2028 according to a new report by MarketsandMarkets™. Market is driven by factors such as High risk of chromosomal abnormalities with advancing maternal age and Increasing number of fertility clinics and IVF centers, as Carrier screening is a genetic testing method designed to identify individuals who carry specific genetic mutations that may be passed on to their offspring. While carrier screening primarily focuses on single gene disorders, chromosomal abnormalities can also be part of the considerations on the other hand, Ethical and Legal Concerns is expected to limit market growth to a certain extent in the coming years. As Genetic information is sensitive and can have implications not only for the individual but also for their family members. Likewise, Integration with Telehealth and Digital Health Platforms and Government initiate and policies are anticipated to propel market growth opportunities as Telehealth eliminates barriers related to geographic distance and transportation, making carrier screening services more accessible to a broader population. Individuals can access genetic counseling and testing services from the comfort of their homes. However, availability of lack of practiced professionals is anticipated to hinder market development.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72642285

Browse in-depth TOC on “Carrier Screening Market”

206 – Tables
48 – Figures
232 – Pages

Key Market Players of Carrier Screening Industry:

The major players in the Carrier Screening Assays Market are Invitae Corporation.(US) , Fulgent Genetics.(US), Eurofins Scientific (Germany), OPKO Health, Inc.(US), Thermo Fisher Scientific Inc.(US), Quest Diagnostics Incorporated (US), Myriad Genetics, Inc (US), Illumina, Inc.(US), Natera, Inc.(Italy), Laboratory Corporation of America Holdings.(US), CENTOGENE N.V.(Germany), and DiaSorin S.p.A.(Italy).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=72642285

Carrier Screening Market Dynamics:

Drivers:

1. Increasing emphasis on early disease detection and prevention
2. Growing prevalence of genetic disorders
3. High risk of chromosomal abnormalities with advancing maternal age
4. Increased focus on preconception and prenatal testing
5. Rising number of fertility clinics and IVF centers
6. Declining rate of fertility

Restraint:

1. Ethical concerns in preconception genetic carrier screening
2. High cost of carrier screening

Opportunities:

1. Increased awareness about reproductive health in emerging economies
2. Integration with telehealth and digital health platforms
3. Increased number of collaborations and partnerships among healthcare organizations
4. Increasing number of government initiatives and policies toward genetic health improvement
5. Growing focus on health screening for rare diseases

Challenge:

1. Lack of skilled professionals
2. Lack of standard guidelines for carrier screening

Enquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=72642285 

Predesigned Panel Testing in Expanded Carrier Screening type segment to witness the highest shares during the forecast period.”

Based on the type, the global Carrier Screening Market is segmented into Expanded Carrier Screening (Customized Panel Testing, Predesigned Panel Testing)., and Targeted Diseases Carrier screening. The Predesigned Panel Testing is expected to dominate because of its wider application. Predesigned testing panels are widely used in carrier screening for several reasons, providing benefits in terms of efficiency, cost-effectiveness, and comprehensive coverage of genetic conditions. The selection of genes and genetic variants included in predesigned panels is often based on extensive evidence and scientific research. These panels are designed to target well-established and clinically relevant genetic mutations associated with specific inherited disorders.

US dominates the North American Carrier Screening Market

Based on the North America region, the Carrier Screening Market is divided into US and Canada. US is expected to dominate the Carrier Screening Market. The United States has a highly advanced and sophisticated healthcare infrastructure, including research facilities, laboratories, and healthcare institutions. This infrastructure supports the development, adoption, and implementation of advanced diagnostic screening such as carrier screening. Similarly, The U.S. is a global hub for biomedical research and innovation. The presence of leading research institutions, academic centers, and biotechnology companies fosters a conducive environment for the development and validation of novel diagnostic as well as research assays.

India dominates the Asia Pacific Carrier Screening Assays Market

The APAC Carrier Screening Market is segmented into Japan, China, India, and Rest of APAC. In 2023, India accounted for the largest share of the Asian Carrier Screening Market. The large share of India can be attributed to the economic growth in the country, there is an increase in the incidence of genetic disorders or a higher prevalence of certain conditions in the Indian population, provides a greater demand for carrier screening services. Likewise, the India has one of the world’s largest populations, and a larger population often translates to a higher number of individuals seeking healthcare services, including carrier screening.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=72642285

Related Reports:

Digital PCR Market – Global Forecasts to 2028

In Vitro Toxicology Testing Market– Global Forecasts to 2028

Immunoassay Market – Global Forecasts to 2028